Inovio Pharmaceuticals, Inc. (INO)
1.145
+0.06
(+5.05%)
USD |
NASDAQ |
Oct 09, 16:00
1.15
0.00 (0.00%)
After-Hours: 20:00
Inovio Pharmaceuticals Cash from Operations (Quarterly) : -18.05M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.05M |
| March 31, 2026 | -21.59M |
| December 31, 2025 | -19.37M |
| September 30, 2025 | -21.57M |
| June 30, 2025 | -20.81M |
| March 31, 2025 | -26.87M |
| December 31, 2024 | -19.66M |
| September 30, 2024 | -27.44M |
| June 30, 2024 | -28.21M |
| March 31, 2024 | -28.76M |
| December 31, 2023 | -26.28M |
| September 30, 2023 | -29.11M |
| June 30, 2023 | -32.31M |
| March 31, 2023 | -36.66M |
| December 31, 2022 | -36.34M |
| September 30, 2022 | -67.47M |
| June 30, 2022 | -50.53M |
| March 31, 2022 | -61.88M |
| December 31, 2021 | -37.89M |
| September 30, 2021 | -46.49M |
| June 30, 2021 | -78.46M |
| March 31, 2021 | -52.87M |
| December 31, 2020 | -51.22M |
| September 30, 2020 | -74.16M |
| June 30, 2020 | -27.15M |
| Date | Value |
|---|---|
| March 31, 2020 | -25.45M |
| December 31, 2019 | -13.74M |
| September 30, 2019 | -27.73M |
| June 30, 2019 | -23.92M |
| March 31, 2019 | -32.45M |
| December 31, 2018 | -17.28M |
| September 30, 2018 | -24.67M |
| June 30, 2018 | -19.02M |
| March 31, 2018 | -12.58M |
| December 31, 2017 | -13.95M |
| September 30, 2017 | -17.31M |
| June 30, 2017 | -16.72M |
| March 31, 2017 | -15.23M |
| December 31, 2016 | -14.90M |
| September 30, 2016 | -18.64M |
| June 30, 2016 | -13.27M |
| March 31, 2016 | -15.74M |
| December 31, 2015 | -6.774M |
| September 30, 2015 | 15.42M |
| June 30, 2015 | -9.022M |
| March 31, 2015 | -12.07M |
| December 31, 2014 | -8.175M |
| September 30, 2014 | -8.043M |
| June 30, 2014 | -8.149M |
| March 31, 2014 | -5.557M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Nektar Therapeutics | -75.77M |
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Fortress Biotech, Inc. | -59.28M |
| Tonix Pharmaceuticals Holding Corp. | -41.87M |
| Kura Oncology, Inc. | -62.55M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 6.147M |
| Cash from Financing (Quarterly) | 17.16M |
| Free Cash Flow | -80.78M |
| Free Cash Flow Per Share (Quarterly) | -0.2211 |
| Free Cash Flow to Equity (Quarterly) | -17.35M |
| Free Cash Flow to Firm (Quarterly) | -18.05M |
| Free Cash Flow Yield | -103.8% |